Small Molecules
1 April 2019
BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-3351401 April 2019
Recida Therapeutics Announces the Initiation of a Phase I Clinical Trial of RC-01, a Novel LpxC Inhibitor30 March 2019
Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-34626 March 2019
Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson26 March 2019
Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society’s Annual Meeting (ENDO)26 March 2019
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib26 March 2019
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25 March 2019
PharmaMar announces positive results in its lurbinectedin monotherapy trial for small cell lung cancer25 March 2019
Forxiga approved in Europe for type-1 diabetesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports